10 май 2013 г. - FDA responded to a petition and the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed.
Добавлено на ленту времени:
Дата:
10 май 2013 г.
Сейчас
~ 12 г назад